Syndax Pharmaceuticals Shares Soar 12.62% on Strong Q2 Earnings

Syndax Pharmaceuticals Inc. (SNDX) shares surged 12.62% in pre-market trading on August 5, 2025, driven by strong financial performance and strategic advancements in its cancer therapy portfolio.

Syndax Pharmaceuticals reported significant financial growth in the second quarter of 2025, with total revenue reaching $38.0 million. This growth was primarily driven by the strong sales of its key products, Revuforj and Niktimvo. Revuforj, an oral menin inhibitor, achieved $28.6 million in net revenue, marking a 43% increase from the previous quarter. Niktimvo, a CSF-1 receptor-blocking antibody, generated $36.2 million in net revenue during its first full quarter post-launch.

The company's robust cash position of $517.9 million is expected to support its path to profitability. Syndax's strategic focus on expanding its product reach is evident in the ongoing clinical trials for Revuforj, targeting various forms of acute leukemia. The company also reported a net loss of $71.8 million for the quarter, reflecting increased research, development, and administrative expenses associated with its expanding operations.

Syndax's management remains optimistic about the future, with expectations of stable expenses and continued revenue growth from its flagship products. The company is poised to achieve profitability, supported by its strong cash reserves and strategic focus on innovative cancer therapies.